# Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

> **NCT02650999** · PHASE1,PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 12 (actual)

## Conditions studied

- CD19+ Diffuse Large B-cell Lymphomas
- Follicular Lymphomas
- Mantle Cell Lymphomas

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02650999
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2019-02-25
- **Final completion:** 2020-06-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02650999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02650999, "Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02650999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*